Spero Therapeutics
SPRO
37 hedge funds and large institutions have $91.2M invested in Spero Therapeutics in 2017 Q4 according to their latest regulatory filings, with 37 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
53.99% more ownership
Funds ownership: 0% → 53.99% (+54%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVAI
Atlas Venture Associates IX
Boston,
Massachusetts
|
+$16.9M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$15M |
| 3 |
AI
Alphabet Inc
Mountain View,
California
|
+$13.7M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$12.6M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$9.82M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| $15K | +$16K | +1,301 | New |
|
27
BNP Paribas Financial Markets
Paris,
France
| $14.6K | +$15.3K | +1,243 | New |
|
28
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $13K | +$13.8K | +1,128 | New |
|
29
Bank of America
Charlotte,
North Carolina
| $12K | +$11.9K | +969 | New |
|
30
Legal & General Group
London,
United Kingdom
| $12K | +$12.5K | +1,019 | New |
|
31
Parallax Volatility Advisers
San Francisco,
California
| $11K | +$11.3K | +924 | New |
|
32
Barclays
London,
United Kingdom
| $11K | +$11.7K | +956 | New |
|
33
Wells Fargo
San Francisco,
California
| $11K | +$12.2K | +990 | New |
|
34
Citigroup
New York
| $8K | +$8.36K | +681 | New |
|
|
AIP
35
Ameritas Investment Partners
Lincoln,
Nebraska
| $6K | +$6.14K | +500 | New |
|
36
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$810 | +66 | New |
|
37
UBS Group
Zurich,
Switzerland
| $1K | +$1.57K | +128 | New |
|
SPRO Hedge Fund Activity: Q4 2017 in Review
37 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q4 2017, worth a combined $91.2M.
Buyers outnumbered sellers: 37 funds opened new SPRO positions and 0 closed out — a net gain of 37 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Atlas Venture Associates IX, opening a new position worth an estimated $16.9M.
- 37 institutional investors held Spero Therapeutics (SPRO) as of Q4 2017, up from 0 in Q3 2017.
- Funds reported $91.2M of Spero Therapeutics stock for Q4 2017.
- 37 funds opened new Spero Therapeutics positions in Q4 2017 and 0 closed out, a net change of +37 holders.
- The largest Spero Therapeutics buyer in Q4 2017 was Atlas Venture Associates IX, an estimated $16.9M added.
Based on aggregated 13F filings for Q4 2017.